intravenous TB-4 Phase 1 safety and pharmacokinetics, no dose-limiting or serious adverse events (Ann N Y Acad Sci 2010;1194:223229): NCT00743769 On February 27, 2026, HHS Secretary Kennedy announced that GHK-Cu is among approximately 14 peptides expected to return to Category 1
Mark your calendars accordingly.
Shipping Ships from Ontario, Canada Availability is shown on this page For additional options, view our full range of research products available in Canada.
If, however, you're designing a study specifically to test the local gut effects of peptides, then an oral formulation might be your test article, but you'd be doing so with the full understanding of its limitations
Compared to larger peptides, which often struggle with poor bioavailability and proteolytic degradation, tripeptides offer a balance of functional stability and conformational flexibility